Study of LM-24C5 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, LM-24C5, for people with advanced solid tumors that have come back or not responded to treatment. It may be an option if your tumor has a specific marker called CEACAM5.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your tumor is advanced and has either come back after treatment or standard treatments no longer work or are not tolerated.
- Your tumor has a specific marker called CEACAM5.
- You are able to perform daily activities with minimal help (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LM-24C5 for people with advanced solid tumors that have stopped responding to standard treatments or who can't tolerate them. It aims to see if the drug is safe and effective.
This study tests a new drug called LM-299 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if LM-299 is safe and effective.
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
This trial tests an experimental drug called LM-350 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This early-phase study tests LM103 in people with advanced solid cancers that have not responded to standard treatments or where standard options are not suitable. It mainly focuses on whether LM103 can be safely given and whether it can shrink tumors or help control the disease.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.